Accessibility Menu
Avalo Therapeutics logo

Avalo Therapeutics(NASDAQ) AVTX

Market Cap$1.06BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)-100%
5 Year-100%
1 Year+112%
1 Month+9%
$19.83
+0.05%
+0.01Today
After hours$19.83-$0.00 (-0.03%)
Avalo Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 19.832026-08-21
Avalo Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.23%USD 19.592026-08-14
1 month+9.26%USD 18.152026-07-22
3 month+21.28%USD 16.352026-05-22
Year to date+9.2%USD 18.162025-12-31
1 year+111.63%USD 9.372025-08-21
3 year-7.37%USD 21.412023-08-22
5 year-99.75%USD 7,977.602021-08-20
Since inception-99.83%USD 11,519.912015-11-13

Avalo Therapeutics Financials at a Glance

Market Cap

$1.06BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$59.00K

Net Income (TTM)

-$100.33M

EPS (TTM)

-$4.74

P/E Ratio

-4.18

Dividend

$0.00

Beta (Volatility)

1.10 (Average)

Price

$19.83

Volume

569,829.779

Open

$20.02

Previous Close

$19.83

Daily Range

$19.58 - $20.19

52-Week Range

$8.65 - $24.27

Estimated Earnings Date

Nov 5, 2026

AVTX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Avalo Therapeutics

Avalo Therapeutics, Inc. makes medicines for painful skin conditions. These treatments help patients manage long-term immune system problems. The company creates new ways to stop body inflammation.

Fighting Chronic Inflammation

  • Abdakibart: Lead antibody candidate designed to treat hidradenitis suppurativa, which is a chronic inflammatory skin condition.
  • AVTX-010: Long-acting medicine in development for patients with immune-mediated inflammatory diseases.
  • Immune-Mediated Therapeutics: Portfolio of drugs targeting specific pathways to reduce swelling and pain in the body.

Strategic Moves and Trials

  • Reported positive Phase 2 LOTUS trial results for its lead drug candidate in the second quarter of 2026.
  • Raised $405.0 million in net proceeds through an equity offering during the second quarter of 2026.
  • Appointed a new director in June 2026 to strengthen its strategic and commercial leadership.
  • Advanced AVTX-010 toward the submission of an investigational new drug application to begin human testing.

What Sets Avalo Apart?

Avalo concentrates on the IL-1β pathway to create targeted therapies for specific inflammatory diseases. The company uses clinical data to support its registrational Phase 3 program for chronic skin conditions.

Measuring Financial Progress

  • Cash and cash equivalents were $472.2 million as of June 30, 2026.
  • Net loss was $56.0 million for the six months ended June 30, 2026.
  • Research and development expenses rose $9.3 million in the second quarter of 2026 compared to the prior year period.
  • Net proceeds from a public equity offering reached $405.0 million in the second quarter of 2026.

Bottom Line

Avalo has shifted its focus toward advanced clinical trials for immune-mediated inflammatory diseases. Its recent capital raise and positive trial results provide a foundation for its transition into late-stage drug development.

AI Generated • Aug 6, 2026

Industry

Biotechnology

Sector

Health Care

Employees

33

CEO

Garry Arthur Neil, MD

Website

www.avalotx.com

Headquarters

Wayne, PA 19087, US

AVTX Financials

Key Financial Metrics (TTM)

Gross Margin

-16861.02%

Operating Margin

-154844.07%

Net Income Margin

-170055.93%

Return on Equity

-58.03%

Return on Capital

-85.32%

Return on Assets

-20.44%

Earnings Yield

-23.92%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.06BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

53.63M

Volume

569.83K

Avg. Volume

1.34M

Financials (TTM)

Gross Profit

-$9.95M

Operating Income

-$91.36M

EBITDA

-$100.04M

Operating Cash Flow

-$66.38M

Capital Expenditure

$0.00

Free Cash Flow

-$66.38M

Cash & ST Invst.

$400.28M

Total Debt

$242.00K

Avalo Therapeutics Performance Analysis

Avalo Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 18,051,000234.4%
20232023-12-31USD 1,924,000-89.3%
20242024-12-31USD 441,000-77.1%
20252025-12-31USD 59,000-86.6%
Avalo Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31-100.0%
Q22026-06-30N/A
Avalo Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1,062.65-55.5%
20232023-12-31USD -113.58-89.3%
20242024-12-31USD -20.91-81.6%
20252025-12-31USD -5.84-72.1%
Avalo Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-14.1%
Q42025-12-3166.2%
Q12026-03-31-32.4%
Q22026-06-3015.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

+100.0%

Gross Margin

0.00%

N/A

Market Cap

$1.06BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$32.23M

N/A

Employees

33

N/A

Net Income

-$36.36M

-75.1%

EBITDA

-$36.31M

-76.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$400.28M

+253.4%

Total Debt

$242.00K

-64.4%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$242.00K

-49.8%

Return on Assets

-20.44%

N/A

Return on Invested Capital

-19.45%

N/A

Free Cash Flow

-$18.08M

-58.7%

Operating Cash Flow

-$18.08M

-58.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ENTAEnanta Pharmaceuticals, Inc.
$13.47+2.59%
PRLDPrelude Therapeutics Incorporated
$6.63+2.00%
OBIOOrchestra BioMed Holdings, Inc.
$5.36-1.29%
IVAInventiva S.A.
$4.68+0.65%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.77+0.10%
IBITiShares Bitcoin Trust
$43.68+0.06%
BITOProShares Trust - ProShares Bitcoin ETF
$10.41+0.06%
MARAMara Holdings
$11.26+0.01%

Questions About AVTX

What is the current price of Avalo Therapeutics?

Avalo Therapeutics is trading at $19.83 per share.

What is the 52-week range for Avalo Therapeutics?

Over the past 52 weeks, Avalo Therapeutics has traded between $8.65 and $24.27.

How much debt does Avalo Therapeutics have?

As of the most recent reporting period, Avalo Therapeutics reported total debt of $2.24M.

How much cash does Avalo Therapeutics have on hand?

Avalo Therapeutics reported $85.43M in cash and cash equivalents in its most recent financial results.

What is Avalo Therapeutics’s dividend yield?

Avalo Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services